허혈성 시신경증 치료 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 약제 클래스별, 투여 경로별, 질환 유형별, 유통 채널별, 지역별

Ischemic Optic Neuropathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

US $ 4,995 ￦ 6,970,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,853,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,791,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 허혈성 시신경증 치료 시장 규모는 완만하게 확대할 태세이며, 2024년 시장 매출은 2억 60만 달러로 추계되고 연간 평균 성장률(CAGR)은 5%로 예측되고 있으며, 2031년말에는 2억 8,610만 달러에 달할 전망입니다. 허혈성 시신경증 치료 시장의 성장을 지원하고 있는 주요 요인은 몇가지 있습니다.

고령화 인구 증가와 증상 악화를 막기 위한 조기 발견의 중요성에 대한 인식이 높아지면서 시신경 장애를 치료하기 위한 수술 및 약물 치료에 대한 관심이 높아져 시장 성장이 가속화되고 있습니다.

시신경 질환의 유병률은 이러한 질환의 치료에 대한 수요를 증가시켜 시장 성장에 기여하고 있습니다. 세계보건기구(WHO)에 따르면 세계에서 13억 명 이상이 시력 장애를 앓고 있습니다. 또한 비침습적 의료 절차에 대한 검안 업계의 선호도가 높아지면서 시장 진출기업에게 매력적인 기회를 제공합니다.

허혈성 시신경병증 치료 시장은 안과 질환을 관리하기 위해 이전에 승인된 안구 임플란트의 사용이 증가함에 따라 더욱 성장할 것으로 예상됩니다. 선진국의 주요 제약사 및 의약품 제조업체들은 성장하는 안과 질환 치료 시장에서 점유율을 확보하기 위해 R&D, 인프라 및 첨단 안과 치료제에 많은 투자를 하고 있으며, 이는 세계 시장 성장을 더욱 가속화하고 있습니다.

세계의 허혈성 시신경증 치료 시장에 대해 조사했으며, 시장의 개요와 약제 클래스별, 투여 경로별, 질환 유형별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업의 경쟁 동향 등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아의 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 허혈성 시신경증 치료 시장 전망, 2018-2031년

• 세계의 허혈성 시신경증 치료 시장 전망, 약제 클래스별, 금액(100만 달러), 2018-2031년
• 세계의 허혈성 시신경증 치료 시장 전망, 투여 경로별, 금액(100만 달러), 2018-2031년
• 세계의 허혈성 시신경증 치료 시장 전망, 질환 유형별, 금액(100만 달러), 2018-2031년
• 세계의 허혈성 시신경증 치료 시장 전망, 유통 채널별, 금액(100만 달러), 2018-2031년
• 세계의 허혈성 시신경증 치료 시장 전망, 지역별, 금액(100만 달러), 2018-2031년

제4장 북미의 허혈성 시신경증 치료 시장 전망, 2018-2031년

제5장 유럽의 허혈성 시신경증 치료 시장 전망, 2018-2031년

제6장 아시아태평양의 허혈성 시신경증 치료 시장 전망, 2018-2031년

제7장 라틴아메리카의 허혈성 시신경증 치료 시장 전망, 2018-2031년

제8장 중동 및 아프리카의 허혈성 시신경증 치료 시장 전망, 2018-2031년

제9장 경쟁 구도

• 약물 클래스와 투여 경로 히트맵
• 제조업체와 투여 경로 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • Oracle Corporation
  • Merge Healthcare Incorporated
  • Medidata Solutions Inc.
  • PAREXEL International Corporation
  • BioClinica
  • MedNet Solutions, Inc.
  • Bio-Optronics, Inc.
  • DSG, Inc.
  • eClinForce, Inc.
  • Forte Research Systems, Inc.

제10장 부록

KSA

영문 목차

영문목차

The worldwide market for Ischemic Optic Neuropathy Treatment is poised for gradual expansion, with the market revenue estimated at US$ 200.6 Mn in 2024, and a projected Compound Annual Growth Rate (CAGR) of 5% expected to reach a valuation of US$ 286.1 Mn by the end of 2031. Several key factors are driving the growth of the market for the treatment of Ischemic Optic Neuropathy.

Growing Aging Population and Awareness Fuel Demand for Treatment

The increasing aging population and a rising awareness of the importance of early detection to prevent further deterioration of the condition have driven interest in surgical procedures and medications for treating optic nerve disorders, leading to accelerated market growth.

Prevalence of Optic Nerve Disorders Spurs Market Demand

The prevalence of optic nerve disorders is boosting the demand for treatments for these conditions, contributing to market growth. According to the World Health Organization (WHO), over 1.3 billion individuals worldwide suffer from eyesight disorders. Additionally, the growing preference for non-invasive medical procedures in the optometric industry is creating attractive opportunities for market players.

R&D Investments Drive Market Expansion

The Ischemic Optic Neuropathy Treatment market is expected to grow further due to increased use of previously approved ocular implants in managing ophthalmology disorders. Leading pharmaceutical and drug manufacturing companies from developed countries are heavily investing in research and development, infrastructure, and advanced ophthalmology therapeutics to capture a share of the growing eye disorder treatment market, further accelerating global market growth.

Factors Driving Market Growth:

• 1. Increasing Adoption of Foreign Direct Investment: The rise in foreign direct investment between European countries, Japan, China, and the ASEAN nations has attracted foreign players to explore markets in India and China, expanding their product reach. Domestic players are also exploring new product development strategies in response to these opportunities.

• 2. Increasing Pool of Diabetic Patients: Ischemic optic neuropathy is commonly associated with diabetes. The increasing prevalence of risk factors such as hypercholesterolemia, diabetes, and hypertension is driving the incidence of this condition.

• 3. Rising Prevalence of Risk Factors: Several risk factors, including reduced blood flow to the optic nerve, increased intraocular pressure, constricted arteries, and others, contribute to ischemic optic neuropathy. These risk factors are associated with various medical conditions, increasing the likelihood of disease development.

Impact on Global Ischemic Optic Neuropathy Treatment Market:

"Severe Side Effects Associated with High-Dose Corticosteroids Medication": High-dose corticosteroids, commonly used as a first-line treatment for ischemic optic neuropathy, can have severe side effects, including heart attack, kidney failure, lung damage, and more. These side effects can adversely affect patients' health and impede market growth.

"High Medication Costs in Underdeveloped Economies": Licensed medications for the treatment of ischemic optic neuropathy can be expensive, making them unaffordable for patients in underdeveloped economies.

Why is the U.S. Ischemic Optic Neuropathy Treatment Market Booming?

"Better Reimbursement Policies": The United States boasts a well-established healthcare infrastructure and facilities, and it currently holds the largest market share globally. Favorable reimbursement policies and high incomes contribute to the growth of the market in the country.

Will Germany Be a Lucrative Market for Manufacturers?

"Highest Number of Older People in the Region and Robust Healthcare System": Germany's sophisticated and organized healthcare system, along with its focus on research and development in the treatment of eye-related disorders, makes it an attractive market for companies worldwide.

Competitive Landscape:

Manufacturers are keen on diversifying their product portfolios by introducing innovative products and securing approvals from various governmental agencies.

Key Companies' Profiled:

• AbbVie Inc.
• Eli Lilly and Company
• GlaxoSmithKline
• Pfizer Inc.
• Teva Pharmaceuticals
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche AG
• Bayer AG
• Sanofi A.S.
• Bristol-Myers Squibb and Company

Market Segmentation

Drug Class:

• Corticosteroids
• Antimetabolites
• Anticoagulants
• Serotonin and norepinephrine reuptake inhibitors (SNRIs)
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Route of Administration:

• Oral
• Injectable

Disease Type:

• Posterior ischemic optic neuropathy
• Anterior ischemic optic neuropathy

Arteritic AION (A-AION)

Non-Arteritic AION (NA-AION)

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Ischemic Optic Neuropathy Treatment Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 3.1. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
    • 3.1.1.2. Web based Ischemic Optic Neuropathy Treatment
    • 3.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 3.2. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. Pharmaceuticals
    • 3.2.1.2. Clinical Research Organizations (CROs)
    • 3.2.1.3. Healthcare Providers
• 3.3. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 3.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 3.4. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. Hospital Pharmacies
    • 3.4.1.2. Retail Pharmacies
    • 3.4.1.3. Drug Stores
    • 3.4.1.4. Online Pharmacies
• 3.5. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
  • 3.5.1. Key Highlights
    • 3.5.1.1. North America
    • 3.5.1.2. Europe
    • 3.5.1.3. Asia Pacific
    • 3.5.1.4. Latin America
    • 3.5.1.5. Middle East & Africa

4. North America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 4.1.1. Key Highlights
  • 4.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
  • 4.1.1.2. Web based Ischemic Optic Neuropathy Treatment
  • 4.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 4.2. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. Pharmaceuticals
    • 4.2.1.2. Clinical Research Organizations (CROs)
    • 4.2.1.3. Healthcare Providers
• 4.3. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 4.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 4.4. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. Hospital Pharmacies
    • 4.4.1.2. Retail Pharmacies
    • 4.4.1.3. Drug Stores
    • 4.4.1.4. Online Pharmacies
• 4.5. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 4.5.1. Key Highlights
    • 4.5.1.1. U.S. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 4.5.1.2. U.S. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.5.1.3. U.S. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 4.5.1.4. U.S. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.1.5. Canada Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 4.5.1.6. Canada Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.5.1.7. Canada Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 4.5.1.8. Canada Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 5.1. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
    • 5.1.1.2. Web based Ischemic Optic Neuropathy Treatment
    • 5.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 5.2. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. Pharmaceuticals
    • 5.2.1.2. Clinical Research Organizations (CROs)
    • 5.2.1.3. Healthcare Providers
• 5.3. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 5.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 5.4. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Hospital Pharmacies
    • 5.4.1.2. Retail Pharmacies
    • 5.4.1.3. Drug Stores
    • 5.4.1.4. Online Pharmacies
• 5.5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 5.5.1. Key Highlights
    • 5.5.1.1. Germany Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.2. Germany Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.3. Germany Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.4. Germany Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.5. U.K. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.6. U.K. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.7. U.K. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.8. U.K. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.9. France Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.10. France Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.11. France Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.12. France Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.13. Italy Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.14. Italy Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.15. Italy Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.16. Italy Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.17. Turkey Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.18. Turkey Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.19. Turkey Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.20. Turkey Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.21. Russia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.22. Russia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.23. Russia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.24. Russia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.1.25. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.5.1.26. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.5.1.27. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.5.1.28. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
    • 6.1.1.2. Web based Ischemic Optic Neuropathy Treatment
    • 6.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 6.2. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. Pharmaceuticals
    • 6.2.1.2. Clinical Research Organizations (CROs)
    • 6.2.1.3. Healthcare Providers
• 6.3. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 6.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 6.4. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. Hospital Pharmacies
    • 6.4.1.2. Retail Pharmacies
    • 6.4.1.3. Drug Stores
    • 6.4.1.4. Online Pharmacies
• 6.5. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 6.5.1. Key Highlights
    • 6.5.1.1. China Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.2. China Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.3. China Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.4. China Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.1.5. Japan Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.6. Japan Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.7. Japan Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.8. Japan Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.1.9. South Korea Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.10. South Korea Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.11. South Korea Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.12. South Korea Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.1.13. India Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.14. India Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.15. India Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.16. India Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.1.17. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.18. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.19. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.20. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.1.21. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.5.1.22. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.5.1.23. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.5.1.24. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 7.1. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
    • 7.1.1.2. Web based Ischemic Optic Neuropathy Treatment
    • 7.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 7.2. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 7.2.1. Key Highlights
    • 7.2.1.1. Pharmaceuticals
    • 7.2.1.2. Clinical Research Organizations (CROs)
    • 7.2.1.3. Healthcare Providers
• 7.3. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 7.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 7.4. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Hospital Pharmacies
    • 7.4.1.2. Retail Pharmacies
    • 7.4.1.3. Drug Stores
    • 7.4.1.4. Online Pharmacies
• 7.5. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 7.5.1. Key Highlights
    • 7.5.1.1. Hardware
    • 7.5.1.2. Services
• 7.6. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 7.6.1. Key Highlights
    • 7.6.1.1. Brazil Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.6.1.2. Brazil Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.6.1.3. Brazil Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.6.1.4. Brazil Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.6.1.5. Mexico Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.6.1.6. Mexico Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.6.1.7. Mexico Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.6.1.8. Mexico Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.6.1.9. Argentina Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.6.1.10. Argentina Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.6.1.11. Argentina Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.6.1.12. Argentina Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
    • 7.6.1.13. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.6.1.14. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.6.1.15. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.6.1.16. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
  • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
    • 8.1.1.2. Web based Ischemic Optic Neuropathy Treatment
    • 8.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
• 8.2. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. Pharmaceuticals
    • 8.2.1.2. Clinical Research Organizations (CROs)
    • 8.2.1.3. Healthcare Providers
• 8.3. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
    • 8.3.1.2. Site based Ischemic Optic Neuropathy Treatment
• 8.4. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. Hospital Pharmacies
    • 8.4.1.2. Retail Pharmacies
    • 8.4.1.3. Drug Stores
    • 8.4.1.4. Online Pharmacies
• 8.5. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
  • 8.5.1. Key Highlights
    • 8.5.1.1. GCC Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.5.1.2. GCC Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.5.1.3. GCC Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.5.1.4. GCC Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.1.5. South Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.5.1.6. South Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.5.1.7. South Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.5.1.8. South Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.1.9. Egypt Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.5.1.10. Egypt Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.5.1.11. Egypt Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.5.1.12. Egypt Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.1.13. Nigeria Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.5.1.14. Nigeria Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.5.1.15. Nigeria Ischemic Optic Neuropathy Treatment Market Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.5.1.16. Nigeria Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.1.17. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.5.1.18. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.5.1.19. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.5.1.20. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
  • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Drug Class vs Route of Administration Heatmap
• 9.2. Manufacturer vs Route of Administration Heatmap
• 9.3. Company Market Share Analysis, 2023
• 9.4. Competitive Dashboard
• 9.5. Company Profiles
  • 9.5.1. Oracle Corporation
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Drug Class Portfolio
    • 9.5.1.3. Financial Overview
    • 9.5.1.4. Business Strategies and Development
  • 9.5.2. Merge Healthcare Incorporated
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Drug Class Portfolio
    • 9.5.2.3. Financial Overview
    • 9.5.2.4. Business Strategies and Development
  • 9.5.3. Medidata Solutions Inc.
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Drug Class Portfolio
    • 9.5.3.3. Financial Overview
    • 9.5.3.4. Business Strategies and Development
  • 9.5.4. PAREXEL International Corporation
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Drug Class Portfolio
    • 9.5.4.3. Financial Overview
    • 9.5.4.4. Business Strategies and Development
  • 9.5.5. BioClinica
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Drug Class Portfolio
    • 9.5.5.3. Financial Overview
    • 9.5.5.4. Business Strategies and Development
  • 9.5.6. MedNet Solutions, Inc.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Drug Class Portfolio
    • 9.5.6.3. Financial Overview
    • 9.5.6.4. Business Strategies and Development
  • 9.5.7. Bio-Optronics, Inc.
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Drug Class Portfolio
    • 9.5.7.3. Financial Overview
    • 9.5.7.4. Business Strategies and Development
  • 9.5.8. DSG, Inc.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Drug Class Portfolio
    • 9.5.8.3. Financial Overview
    • 9.5.8.4. Business Strategies and Development
  • 9.5.9. eClinForce, Inc.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Drug Class Portfolio
    • 9.5.9.3. Financial Overview
    • 9.5.9.4. Business Strategies and Development
  • 9.5.10. Forte Research Systems, Inc.
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Drug Class Portfolio
    • 9.5.10.3. Financial Overview
    • 9.5.10.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료